$CTSO

CytoSorbents (CTSO) reported Q3 2026 revenue of $9.7M, up 3% YoY, with improved gross margin (75%) and reduced operating expenses (-11%). Operating cash flow breakeven was achieved, excluding restructuring costs. Nine-month revenue was $28.2M, with net loss improving 42% YoY. CEO Phillip Chan highlighted progress on four value drivers, including sustainable cash flow and U.S. market expansion.

Cytosorbents Corporation (CTSO) will release Q3'26 earnings on October 29. Analysts expect revenue of $9.90M and EPS of -$0.90. The announcement is scheduled for 8:00 AM ET.

WBB Securities initiated coverage on CytoSorbents (CTSO) with a Speculative Buy rating and $9.50 price target, citing business restructuring and expected profitability in 2027. The company reported $9.6M Q2 2026 revenue, a 73% gross margin, and improved operating losses. Analysts predict profitability this year, supporting a turnaround thesis.

CytoSorbents (CTSO) announced it regained compliance with Nasdaq's minimum bid price requirement of $1.00 per share. The company's stock closed at or above this price for 10 consecutive trading sessions. CytoSorbents is also working to meet other Nasdaq listing requirements by December 28, 2026. The company aims to drive sales, achieve cash flow breakeven, and advance regulatory approvals for its products.

Cytosorbents Corp (CTSO) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 CytoSorbents Regains Compliance with Nasdaq Minimum Bid Price Requirement PRINCETON, N.J., September 23, 2026 -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blo

Chan Phillip P. (Chief Executive Officer) purchased 3,774 shares of Cytosorbents Corp (CTSO) at $6.00 on 2026-09-15.

Capponi Vincent (President and COO) purchased 2,073 shares of Cytosorbents Corp (CTSO) at an average of $6.05 ($5.90–$6.07) across 2 trades on 2026-09-14.

Sobel Alan D. purchased 2,500 shares of Cytosorbents Corp (CTSO) at an average of $6.10 ($6.01–$6.12) across 3 trades on 2026-09-15.

Chan Phillip P. (Chief Executive Officer) purchased 200,000 shares of Cytosorbents Corp (CTSO) at $0.35 on 2026-09-04.

Cytosorbents Corp (CTSO) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders CytoSorbents Corporation (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”) on August 13, 2026. At the Annual Meeting, the following matters were submitted to a vote of stockholders: 1.